News und Analysen
BOIRON : Acquisition of trademarks and patents
The BOIRON Laboratories have acquired from the Swiss company ALKANTIS the trademarks and patents relating to its medical device for analgesic, anti-inflammatory and anti-oedematous purposes....
Is the Stock Market Overpriced? Yes -- but Not These 3 Sectors
Is the stock market overpriced? Consider that the historical price-to-earnings (P/E) ratio for the S&P 500 over the past 146 years is 15.6. The current earnings multiple is over 25.5 -- more....
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that.....
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that.....
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that.....
Why ImmunoGen, Inc. Jumped Higher Today
Shares of ImmunoGen (NASDAQ: IMGN) closed up 12% as the American Society of Hematology (ASH) meeting wraps up. The biotech presented over the weekend, which shouldn't be affecting the price of....
Is Illumina, Inc. a Buy?
2017 has been an excellent year for Illumina (NASDAQ: ILMN), the market leader for gene sequencers, having revived sales growth thanks to the rollout of a new product line. Shareholders have been....
Is Illumina, Inc. a Buy?
2017 has been an excellent year for Illumina (NASDAQ: ILMN), the market leader for gene sequencers, having revived sales growth thanks to the rollout of a new product line. Shareholders have been....
Is Illumina, Inc. a Buy?
2017 has been an excellent year for Illumina (NASDAQ: ILMN), the market leader for gene sequencers, having revived sales growth thanks to the rollout of a new product line. Shareholders have been....
Here's Why Everyone's So Excited About bluebird bio
Investors have seen bluebird bio's (NASDAQ: BLUE) share price skyrocket following impressive early-stage trial results for bb2121, a multiple myeloma gene therapy that's licensed to Celgene Corp.....
5 Biotech Buyout Candidates for 2018
With the Republican tax plan steaming through both houses of Congress, 2018 is shaping up to be a banner year in terms of consolidation for the biotechnology industry. Biopharmaceutical....
Why 2017 Was a Year to Forget for Pfizer Inc.
The S&P 500 index soared 19% in 2017 (so far). The healthcare sector performed even better, with year-to-date gains of close to 21%. Several major drugmakers completed significant....
Why 2017 Was a Year to Forget for Pfizer Inc.
The S&P 500 index soared 19% in 2017 (so far). The healthcare sector performed even better, with year-to-date gains of close to 21%. Several major drugmakers completed significant....
AbbVie Makes Progress on Quest to Diversify
AbbVie's (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide....
This Is Why Global Blood Therapeutics Inc. Is Sinking Today
In response to the company announcing data from a case study at the American Society of Hematology meeting in Atlanta, shares of Global Blood Therapeutics (NASDAQ: GBT), a clinical-stage biotech....
3 Reasons Spark Therapeutics Is a Buy After Its Crash
After Spark Therapeutics and competitor BioMarin Therapeutic (NASDAQ: BMRN) updated investors on the progress that they're making developing competing gene therapies for hemophilia, investors....
Here's Why Inovio Pharmaceuticals Inc. Fell 21.3% in November
Shares of Inovio Pharmaceuticals Inc. (NASDAQ: INO), a biopharmaceutical company developing vaccines, fell 21.3% in November according to data from S&P Global Market Intelligence. Despite....
Here's Why GlycoMimetics Is Soaring 24.3% Higher Today
After unveiling updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML), GlycoMimetics (NASDAQ: GLYC) shares are surging 24.3% as of noon EST....
BASTIDE : ACQUISITION OF UK-BASED BAYWATER HEALTHCARE
Bastide Group has announced that it has signed an agreement for the acquisition of the entire share capital of Baywater Healthcare, previously owned by European investment fund Duke....
BASTIDE : ACQUISITION DE LA SOCIETE ANGLAISE BAYWATER HEALTHCARE
Le Groupe Bastide annonce avoir conclu un protocole d'accord portant sur l'acquisition de 100% du capital de la société Baywater Healthcare, détenue auparavant par le fonds d'investissement....
Here's Why Omeros Corporation Is Gaining More Ground Today
Shares of Omeros Corporation (NASDAQ: OMER) rose as high as 10.8% this morning after the biotech announced a U.S. Food and Drug Administration approval that expands its commercial-stage drug to....
3 Top Healthcare Stocks to Buy in December
If you're looking to put some healthcare stocks in your portfolio this holiday season, then it could be a very good time to consider Welltower Inc (NYSE: HCN), Geron Corporation (NASDAQ: GERN),....
3 Dividend Stocks to Buy on Sale
Stocks that pay out the highest dividend yields aren't always the best ones to buy. Sometimes, the yields are artificially high in advance of a big dividend cut. And sometimes the dividend is....
These 3 Stocks Just Raised Their Dividends
We're getting down to the wire now, with only a few short weeks until the close of 2017. It was a year nearly full to the brim with dividend raises, so income investors will be sorry to see it....
3 Dividend Stocks to Buy on Sale
Stocks that pay out the highest dividend yields aren't always the best ones to buy. Sometimes, the yields are artificially high in advance of a big dividend cut. And sometimes the dividend is....